Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-center, Open-label, Single Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreal Injection of IGT001 in Adult Patients With Retinitis Pigmentosa

NCT06936787 is registered in ClinicalTrials.gov with Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine as lead sponsor.

NCT NCT06936787
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06936787 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-center, Open-label, Single Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreal Injection of IGT001 in Adult Patients With Retinitis Pigmentosa
Lead sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase
Phase 1
Overall status
Recruiting
Start date
April 20, 2025
Completion date
December 20, 2027
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

retinitis pigmentosa